Orexin receptor antagonists as therapeutic agents for insomnia

Frontiers in Pharmacology

Volumn 4 DEC, Issue , 2013, Pages

  Equihua, Ana C ^a   De La Herrán Arita, Alberto K ^b   Drucker Colin, Rene ^a  

^a INSTITUTO DE FISIOLOGÍA CELULAR   (Mexico)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hypocretins orexins; Insomnia; Orexin receptor antagonist; Sleep disorders; Therapy related

Indexed keywords

1 (2 METHYL 6 BENZOXAZOLYL) 3 (1,5 NAPHTHYRIDIN 4 YL)UREA; 1 (6,8 DIFLUORO 2 METHYL 4 QUINOLINYL) 3 (4 DIMETHYLAMINOPHENYL)UREA; ACT 335827; AK 335827; ALMOREXANT; DORA 30; DOXEPIN; EMPA; ESTAZOLAM; ESZOPICLONE; FILOREXANT; FLURAZEPAM; HYPNOTIC SEDATIVE AGENT; JNJ 10397049; OREXIN; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; OREXIN RECEPTOR; QUAZEPAM; RAMELTEON; SB 649868; SB 674042; SUVOREXANT; TCS OX2 29; TEMAZEPAM; TRIAZOLAM; UNCLASSIFIED DRUG; ZALEPLON; ZOLPIDEM;

ABNORMAL BEHAVIOR; ABNORMAL DREAMING; ALLERGIC REACTION; AMNESIA; BEHAVIOR DISORDER; BLURRED VISION; COGNITIVE THERAPY; COORDINATION DISORDER; DAYTIME SOMNOLENCE; DEPRESSION; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG MEGADOSE; DRUG RECEPTOR BINDING; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; HYPNAGOGIC HALLUCINATION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSOMNIA; LOW DRUG DOSE; NARCOLEPSY; NAUSEA; NEUROBIOLOGY; NONHUMAN; NONREM SLEEP; PARASOMNIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY INSOMNIA; PROTEIN FUNCTION; RECOMMENDED DRUG DOSE; REM SLEEP; REVIEW; RHINOPHARYNGITIS; SLEEP TIME; SLEEP WAKING CYCLE; SOMNOLENCE; SORE THROAT; SUICIDAL IDEATION; THOUGHT DISORDER; UNSPECIFIED SIDE EFFECT; VOMITING; WAKEFULNESS; XEROSTOMIA;

EID: 84891707969     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2013.00163     Document Type: Review

References (89)

1. Adam, K., Tomeny, M., and Oswald, I. (1986). Physiological and psychological differences between good and poor sleepers. J. Psychiatr. Res. 20, 301-316. doi: 10.1016/0022-3956(86)90033-6.
2. Adamantidis, A. R., Zhang, F., Aravanis, A. M., Deisseroth, K., and de Lecea, L. (2007). Neural substrates of awakening probed with optogenetic control of hypocretin neurons. Nature 450, 420-424. doi: 10.1038/nature06310.
3. Al-Barazanji, K. A., Wilson, S., Baker, J., Jessop, D. S., and Harbuz, M. S. (2001). Central orexin-A activates hypothalamic-pituitary-adrenal axis and stimulates hypothalamic corticotropin releasing factor and arginine vasopressin neurones in conscious rats. J. Neuroendocrinol. 13, 421-424. doi: 10.1046/j.1365-2826.2001.00655.x.
4. Alexandre, C., Andermann, M. L., and Scammell, T. E. (2013). Control of arousal by the orexin neurons. Curr. Opin. Neurobiol. 23, 1-8. doi: 10.1016/j.conb.2013.04.008.
5. Bartter, F. C., Delea, C. S., and Halberg, F. (2006). A map of blood and urinary changes related to circadian variations in adrenal cortical function in normal subjects. Ann. N.Y. Acad. Sci. 98, 969-983. doi: 10.1111/j.1749-6632.1962.tb30612.x.
6. Bettica, P., Squassante, L., Zamuner, S., Nucci, G., Danker-Hopfe, H., and Ratti, E. (2012). The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia. Sleep 35, 1097-1104. doi: 10.5665/sleep.1996.
7. Bonnet, M. H., and Arand, D. L. (2010). Hyperarousal and insomnia: state of the science. Sleep Med. Rev. 14, 9-15. doi: 10.1016/j.smrv.2009.05.002.
8. Borbély, A. A., Mattmann, P., Loepfe, M., Strauch, I., and Lehmann, D. (1985). Effect of benzodiazepine hypnotics on all-night sleep EEG spectra. Hum Neurobiol., 4, 189-194.
9. Bourgin, P., Huitrón-Résendiz, S., Spier, A. D., Fabre, V., Morte, B., Criado, J. R., et al. (2000). Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons. J. Neurosci. 20, 7760-7765.
10. Brisbare-Roch, C., Dingemanse, J., Koberstein, R., Hoever, P., Aissaoui, H., Flores, S., et al. (2007). Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat. Med. 13, 150-155. doi: 10.1038/nm1544.
11. Buckley, T. M., and Schatzberg, A. F. (2005). On the interactions of the hypothalamic-pituitary-adrenal (HPA) axis and sleep: normal HPA axis activity and circadian rhythm, exemplary sleep disorders. J. Clin. Endocrinol. Metab. 90, 3106-3114. doi: 10.1210/jc.2004-1056.
12. Chang, H., Saito, T., Ohiwa, N., Tateoka, M., Deocaris, C. C., Fujikawa, T., et al. (2007). Inhibitory effects of an orexin-2 receptor antagonist on orexin A-and stress-induced ACTH responses in conscious rats. Neurosci. Res. 57, 462-466. doi: 10.1016/j.neures.2006.11.009.
13. Chapotot, F., Buguet, A., Gronfier, C., and Brandenberger, G. (2001). Hypothalamo-pituitary-adrenal axis activity is related to the level of central arousal: effect of sleep deprivation on the association of high-frequency waking electroencephalogram with cortisol release. Neuroendocrinology 73, 312-321. doi: 10.1159/000054648.
14. Chemelli, R., Willie, J., and Sinton, C. M. (1999). Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98, 437-451. doi: 10.1016/S0092-8674(00)81973-X.
15. De la Herrán-Arita, A. K., Zomosa-Signoret, V. C., Millán-Aldaco, D. A., Palomero-Rivero, M., Guerra-Crespo, M., et al. (2011). Aspects of the narcolepsy-cataplexy syndrome in O/E3-null mutant mice. Neuroscience 183, 134-143. doi: 10.1016/j.neuroscience.2011.03.029.
16. Del Cid-Pellitero, E., and Garzón, M. (2011). Hypocretin1/OrexinA-containing axons innervate locus coeruleus neurons that project to the Rat medial prefrontal cortex. Implication in the sleep-wakefulness cycle and cortical activation. Synapse 65, 843-857. doi: 10.1002/syn.20912.
17. de Lecea, L., Kilduff, T., Peyron, C., Gao, X., Foye, P., Danielson, P., et al. (1998). The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. U.S.A. 95, 322-327. doi: 10.1073/pnas.95.1.322.
18. Di Fabio, R., Pellacani, A., Faedo, S., Roth, A., Piccoli, L., Gerrard, P., et al. (2011). Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders. Bioorg. Med. Chem. Lett. 21, 5562-5567. doi: 10.1016/j.bmcl.2011.06.086.
19. Dollins, A. B., Zhdanova, I. V., Wurtman, R. J., Lynch, H. J., and Deng, M. H. (1994). Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc. Natl. Acad. Sci. U.S.A. 91, 1824-1828. doi: 10.1073/pnas.91.5.1824.
20. Dugovic, C., Shelton, J. E., Aluisio, L. E., Fraser, I. C., Jiang, X., Sutton, S. W., et al. (2009). Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J. Pharmacol. Exp. Ther. 330, 142-151. doi: 10.1124/jpet.109.152009.
21. Edinger, J. D., Glenn, D. M., Bastian, L. A., Marsh, G. R., Dailey, D., Hope, T. V., et al. (2003). Daytime testing after laboratory or home-based polysomnography: comparisons of middle-aged insomnia sufferers and normal sleepers. J. Sleep Res. 12, 43-52. doi: 10.1046/j.1365-2869.2003.00335.x.
22. Erman, M., Seiden, D., Zammit, G., Sainati, S., and Zhang, J. (2006). An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med. 7, 17-24. doi: 10.1016/j.sleep.2005.09.004.
23. España, R. A., Baldo, B. A., Kelley, A. E., and Berridge, C. W. (2001). Wake-promoting and sleep-suppressing actions of hypocretin (orexin): basal forebrain sites of action. Neuroscience 106, 699-715. doi: 10.1016/S0306-4522(01)00319-0.
24. Furlong, T. M., Vianna, D. M. L., Liu, L., and Carrive, P. (2009). Hypocretin/orexin contributes to the expression of some but not all forms of stress and arousal. Eur. J. Neurosci. 30, 1603-1614. doi: 10.1111/j.1460-9568.2009.06952.x.
25. Gaillard, J.-M., Schulz, P., and Tissot, R. (2009). Effects of three Benzodiazepines (Nitrazepam, Flunitrazepam and Bromazepam) on sleep of normal subjects, studied with an automatic sleep scoring system. Pharmacopsychiatry 6, 207-217. doi: 10.1055/s-0028-1094383.
26. Gozzi, A., Turrini, G., Piccoli, L., Massagrande, M., Amantini, D., Antolini, M., et al. (2011). Functional magnetic resonance imaging reveals different neural substrates for the effects of orexin-1 and orexin-2 receptor antagonists. PLoS ONE 6:e16406. doi: 10.1371/journal.pone.0016406.
27. Gunja, N. (2013). In the Zzz zone: the effects of z-drugs on human performance and driving. J. Med. Toxicol. 9, 163-171. doi: 10.1007/s13181-013-0294-y.
28. Hagan, J. J., Leslie, R. A., Patel, S., Evans, M. L., Wattam, T. A., Holmes, S., et al. (1999). Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc. Natl. Acad. Sci. U.S.A. 96, 10911-10916. doi: 10.1073/pnas.96.19.10911.
29. Herring, W. J., Snyder, E., Budd, K., Hutzelmann, J., Snavely, D., Liu, K., et al. (2012). Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology 79, 2265-2274. doi: 10.1212/WNL.0b013e31827688ee.
30. Hoever, P., Dorffner, G., Beneš, H., Penzel, T., Danker-Hopfe, H., Barbanoj, M. J., et al. (2012). Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial. Clin. Pharmacol. Ther. 91, 975-985. doi: 10.1038/clpt.2011.370.
31. Huang, Z. L., Qu, W. M., Li, W. D., Mochizuki, T., Eguchi, N., Watanabe, T., et al. (2001). Arousal effect of orexin A depends on activation of the histaminergic system. Proc. Natl. Acad. Sci. U.S.A. 98, 9965-9970. doi: 10.1073/pnas.181330998.
32. Jacobs, G. D., Pace-Schott, E. F., Stickgold, R., and Otto, M. W. (2004). Cognitive behavior therapy and pharmacotherapy for insomnia: a randomized controlled trial and direct comparison. Arch. Intern. Med. 164, 1888-1896. doi: 10.1001/archinte.164.17.1888.
33. Johnson, M. W., Suess, P. E., and Griffiths, R. R. (2006). Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch. Gen. Psychiatry 63, 1149-1157. doi: 10.1001/archpsyc.63.10.1149.
34. Johnson, P. L., Truitt, W., Fitz, S. D., Minick, P. E., Dietrich, A., Sanghani, S., et al. (2010). A key role for orexin in panic anxiety. Nat. Med. 16, 111-115. doi: 10.1038/nm.2075.
35. Jupp, B., Krivdic, B., Krstew, E., and Lawrence, A. J. (2011). The orexin receptor antagonist SB-334867 dissociates the motivational properties of alcohol and sucrose in rats. Brain Res. 1391, 54-59. doi: 10.1016/j.brainres.2011.03.045.
36. Kalogiannis, M., Hsu, E., Willie, J. T., Chemelli, R. M., Kisanuki, Y. Y., Yanagisawa, M., et al. (2011). Cholinergic modulation of narcoleptic attacks in double orexin receptor knockout mice. PLoS ONE 6:e18697. doi: 10.1371/journal.pone.0018697.
37. Kay, G. G. (2000). The effects of antihistamines on cognition and performance. J. Allergy Clin. Immunol. 105, S622-S627. doi: 10.1067/mai.2000.106153.
38. Kiyashchenko, L., Mileykovskiy, B., Maidment, N., Lam, H. A., Wu, M.-F., John, J., et al. (2002). Release of Hypocretin (Orexin) during waking and sleep states. J. Neurosci. 22, 5282-5286.
39. Köhler, C., Swanson, L. W., Haglund, L., and Wu, J. Y. (1985). The cytoarchitecture, histochemistry and projections of the tuberomammillary nucleus in the rat. Neuroscience 16, 85-110. doi: 10.1016/0306-4522(85)90049-1.
40. Kummangal, B. A., Kumar, D., and Mallick, H. N. (2013). Intracerebroventricular injection of orexin-2 receptor antagonist promotes REM sleep. Behav. Brain Res. 237, 59-62. doi: 10.1016/j.bbr.2012.09.015.
41. Lader, M. (2012). Benzodiazepine harm: how can it be reduced? Br. J. Clin. Pharmacol. 1-19. doi: 10.1111/j.1365-2125.2012.04418.x.
42. Lanoir, J., and Killam, E. K. (1968). Alteration in the sleep-wakefulness patterns by benzodiazepines in the cat. Electroencephalogr. Clin. Neurophysiol. 25, 530-542. doi: 10.1016/0013-4694(68)90232-0.
43. Lebold, T. P., Bonaventure, P., and Shireman, B. T. (2013). Selective orexin receptor antagonists. Bioorg. Med. Chem. Lett. 23, 4761-4769. doi: 10.1016/j.bmcl.2013.06.057.
44. Lee, M. G., Hassani, O. K., and Jones, B. E. (2005). Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. J. Neurosci. 25, 6716-6720. doi: 10.1523/JNEUROSCI.1887-05.2005.
45. Lin, L., Faraco, J., Li, R., Kadotani, H., Rogers, W., Lin, X., et al. (1999). The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98, 365-376. doi: 10.1016/S0092-8674(00)81965-0.
46. Mang, G. M., Dürst, T., Bürki, H., Imobersteg, S., Abramowski, D., Schuepbach, E., et al. (2012). The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors. Sleep 35, 1625-1635. doi: 10.5665/sleep.2232.
47. Marcus, J. N., Aschkenasi, C. J., Lee, C. E., Chemelli, R. M., Saper, C. B., Yanagisawa, M., et al. (2001). Differential expression of orexin receptors 1 and 2 in the rat brain. J. Comp. Neurol. 435, 6-25. doi: 10.1002/cne.1190.
48. Meoli, A., Rosen, C., Kristo, D., Kohrman, M., Gooneratne, N., Aguillard, R., et al. (2005). Oral nonprescription treatment for insomnia: an evaluation of products with limited evidence. J. Clin. Sleep Med. 1, 173-187.
49. Mieda, M., Hasegawa, E., Kisanuki, Y. Y., Sinton, C. M., Yanagisawa, M., and Sakurai, T. (2011). Differential roles of orexin receptor-1 and-2 in the regulation of non-REM and REM sleep. J. Neurosci. 31, 6518-6526. doi: 10.1523/JNEUROSCI.6506-10.2011.
50. Mileykovskiy, B. Y., Kiyashchenko, L. I., and Siegel, J. M. (2005). Behavioral correlates of activity in identified hypocretin/orexin neurons. Neuron 46, 787-798. doi: 10.1016/j.neuron.2005.04.035.
51. Monroe, L. (1967). Psychological and physiological differences between good and poor sleepers. J. Abnorm. Psychol. 72, 255-264. doi: 10.1037/h0024563.
52. Morairty, S. R., Revel, F. G., Malherbe, P., Moreau, J.-L., Valladao, D., Wettstein, J. G., et al. (2012). Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone. PLoS ONE 7:e39131. doi: 10.1371/journal.pone.0039131.
53. Morin, C. M. (1999). Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA 281, 991. doi: 10.1001/jama.281.11.991.
54. Morin, C. M., Culbert, J., and Schwartz, S. (1994). Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy. Am. J. Psichiatr. 151, 1172-1180.
55. NIH State-of-the-Science Conference Statement on Manifestations Management of Chronic Insomnia in Adults. (2005). NIH Consens Sci Statements, Vol. 22.
56. Pandi-Perumal, S. R., Spence, D. W., Verster, J. C., Srinivasan, V., Brown, G. M., Cardinali, D. P., et al. (2011). Pharmacotherapy of insomnia with ramelteon: safety, efficacy and clinical applications. J. Cent. Nerv. Syst. Dis. 3, 51-65. doi: 10.4137/JCNSD.S1611.
57. Panula, P., Pirvola, U., Auvinen, S., and Airaksinen, M. (1989). Histamine-immunoreactive nerve fibers in the rat brain. Neuroscience 28, 585-610. doi: 10.1016/0306-4522(89)90007-9.
58. Perlis, M. L., Smith, M. T., Andrews, P. J., Orff, H., and Giles, D. E. (2001). Beta/Gamma EEG activity in patients with primary and secondary insomnia and good sleeper controls. Sleep 24, 110-117.
59. Peyron, C., Tighe, D. K., van den Pol, A., de Lecea, L., Heller, H. C., Sutcliffe, J. G., et al. (1998). Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. 18, 9996-10015.
60. Piper, D. C., Upton, N., Smith, M. I., and Hunter, A. J. (2000). The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats. Eur. J. Neurosci. 12, 726-730. doi: 10.1046/j.1460-9568.2000.00919.x.
61. Prober, D. A., Rihel, J., Onah, A. A., Sung, R.-J., and Schier, A. F. (2006). Hypocretin/orexin overexpression induces an insomnia-like phenotype in zebrafish. J. Neurosci. 26, 13400-13410. doi: 10.1523/JNEUROSCI.4332-06.2006.
62. Pruessner, J., Wolf, O., Hellhammer, D., Buske-Kirschbaum, A., von Auer, K., Jobst, S., et al. (1997). Free cortisol levels after awakening: a reliable biological marker for the assessment of adrenocortical activity. Life Sci. 61, 2539-2549. doi: 10.1016/S0024-3205(97)01008-4.
63. Reiter, R. J. (1986). Normal patterns of melatonin levels in the pineal gland and body fluids of humans and experimental animals. J. Neural Transm. Suppl. 21, 35-54.
64. Richardson, G. S., and Roth, T. (2001). Future directions in the management of insomnia. J. Clin. Psychiatry 62, 39-45.
65. Richelson, E. (1979). Tricyclic antidepressants and histamine H1 receptors. Mayo Clin. Proc. 54, 669-674.
66. Risberg, A., Risberg, J., and Ingvar, D. (1975). Effects of promethazine on nocturnal sleep in normal man. Psychopharmacologia 43, 279-284. doi: 10.1007/BF00429264.
67. Rudolph, U., and Knoflach, F. (2011). Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nat. Rev. Drug Discov. 10, 685-697. doi: 10.1038/nrd3502.
68. Saitou, K., Kaneko, Y., Sugimoto, Y., Chen, Z., and Kamei, C. (1999). Slow wave sleep-inducing effects of first generation H1-antagonists. Biol. Pharm. Bull. 22, 1079-1082. doi: 10.1248/bpb.22.1079.
69. Sakamoto, F., Yamada, S., and Ueta, Y. (2004). Centrally administered orexin-A activates corticotropin-releasing factor-containing neurons in the hypothalamic paraventricular nucleus and central amygdaloid nucleus of rats: possible involvement of central orexins on stress-activated central CRF neurons. Regul. Pept. 118, 183-191. doi: 10.1016/j.regpep.2003.12.014.
70. Sakurai, T. (2007). The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat. Rev. Neurosci. 8, 171-181. doi: 10.1038/nrn2092.
71. Sakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R. M., Tanaka, H., et al. (1998). Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92, 573-585. doi: 10.1016/S0092-8674(00)80949-6.
72. Smart, D., Sabido-David, C., Brough, S. J., Jewitt, F., Johns, A., Porter, R. A., et al. (2001). SB-334867-A: the first selective orexin-1 receptor antagonist. Br. J. Pharmacol. 132, 1179-1182. doi: 10.1038/sj.bjp.0703953.
73. Smith, M. I., Piper, D. C., Duxon, M. S., and Upton, N. (2003). Evidence implicating a role for orexin-1 receptor modulation of paradoxical sleep in the rat. Neurosci. Lett. 341, 256-258. doi: 10.1016/S0304-3940(03)00066-1.
74. Smith, R. J., and Aston-Jones, G. (2012). Orexin / hypocretin 1 receptor antagonist reduces heroin self-administration and cue-induced heroin seeking. Eur. J. Neurosci. 35, 798-804. doi: 10.1111/j.1460-9568.2012.08013.x.
75. Spath-Schwalbe, E. (1992). Nocturnal adrenocorticotropin and cortisol secretion depends on sleep duration and decreases in association with spontaneous awakening in the morning. J. Clin. Endocrinol. Metab. 75, 1431-1435. doi: 10.1210/jc.75.6.1431.
76. Steiger, A., Guldner, J., Knisatschek, H., Rothe, B., Lauer, C., and Holsboer, F. (1991). Effects of an ACTH/MSH(4-9) analog (HOE 427) on the sleep EEG and nocturnal hormonal secretion in humans. Peptides 12, 1007-1010. doi: 10.1016/0196-9781(91)90051-P.
77. Steiner, M. A., Gatfield, J., Brisbare-Roch, C., Dietrich, H., Treiber, A., Jenck, F., et al. (2013). Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist. ChemMedChem 8, 898-903. doi: 10.1002/cmdc.201300003.
78. Stepanski, E., Zorick, F., Roehrs, T., Young, D., and Roth, T. (1988). Daytime alertness in patients with chronic insomnia compared with asymptomatic control subjects. Sleep 11, 54-60.
79. Sun, H., Kennedy, W. P., Wilbraham, D., Lewis, N., Calder, N., Li, X., et al. (2013). Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep 36, 259-267. doi: 10.5665/sleep.2386.
80. Thannickal, T. C., Moore, R. Y., Nienhuis, R., Ramanathan, L., Gulyani, S., Aldrich, M. S., et al. (2000). Reduced number of hypocretin neurons in human narcolepsy. Neuron 27, 469-474. doi: 10.1016/S0896-6273(00)00058-1.
81. Vgontzas, A. N., Bixler, E. O., Lin, H. M., Prolo, P., Mastorakos, G., Vela-Bueno, A., et al. (2001). Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implications. J. Clin. Endocrinol. Metab. 86, 3787-3794. doi: 10.1210/jc.86.8.3787.
82. Weber, J., Siddiqui, M. A., Wagstaff, A. J., and McCormack, P. L. (2010). Low-dose doxepin: in the treatment of insomnia. CNS Drugs 24, 713-720. doi: 10.2165/11200810-000000000-00000.
83. White, C. L., Ishii, Y., Mendoza, T., Upton, N., Stasi, L. P., Bray, G. A., et al. (2005). Effect of a selective OX1R antagonist on food intake and body weight in two strains of rats that differ in susceptibility to dietary-induced obesity. Peptides 26, 2331-2338. doi: 10.1016/j.peptides.2005.03.042.
84. Willie, J. T., Chemelli, R. M., Sinton, C. M., Tokita, S., Williams, S. C., Kisanuki, Y. Y., et al. (2003). Distinct narcolepsy syndromes in orexin receptor-2 and orexin null mice. Neuron 38, 715-730. doi: 10.1016/S0896-6273(03)00330-1.
85. Willie, J. T., Takahira, H., Shibahara, M., Hara, J., Nomiyama, M., Yanagisawa, M., et al. (2011). Ectopic overexpression of orexin alters sleep/wakefulness states and muscle tone regulation during REM sleep in mice. J. Mol. Neurosci. 43, 155-161. doi: 10.1007/s12031-010-9437-7.
86. Winrow, C. J., Gotter, A. L., Cox, C. D., Doran, S. M., Tannenbaum, P. L., Breslin, M. J., et al. (2011). Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist. J. Neurogenet. 25, 52-61. doi: 10.3109/01677063.2011.566953.
87. Winsky-Sommerer, R., Yamanaka, A., Diano, S., Borok, E., Roberts, A. J., Sakurai, T., et al. (2004). Interaction between the corticotropin-releasing factor system and hypocretins (orexins): a novel circuit mediating stress response. J. Neurosci. 24, 11439-11448. doi: 10.1523/JNEUROSCI.3459-04.2004.
88. Xi, M., Morales, F. R., and Chase, M. H. (2001). Effects on sleep and wakefulness of the injection of hypocretin-1 (orexin-A) into the laterodorsal tegmental nucleus of the cat. Brain Res. 901, 259-264. doi: 10.1016/S0006-8993(01)02317-4.
89. Zhdanova, I., Wurtman, R., Morabito, C., Piotrovska, V., and Lynch, H. (1996). Effects of low oral doses of melatonin, given 2-4 h before habitual bedtime, on sleep in normal young humans. Sleep 19, 423-431.